The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI

Authors: Megan Garland, Andrew J. Hryckowian, Martina Tholen, Kristina Oresic Bender, William W. Van Treuren, Sebastian Loscher, Justin L. Sonnenburg, Matthew Bogyo - Cell Reports Medicine 2020 cited by 47

-infected mice. This increased microbiome recovery upon ebselen treatment correlates with a decrease in host-derived inflammatory markers, suggesting that the anti-inflammatory properties of ebselen, combined with its anti-toxin function, help to mitigate the major clinical challenges of CDI, including recurrence, microbial dysbiosis, and colitis.